Somatic Alterations and Tumor Mutational Burden (TMB) in Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFiRI Plus Bevacizumab or Cetuximab (Fire-3 Trial)-MedSci.cn

Somatic Alterations and Tumor Mutational Burden (TMB) in Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFiRI Plus Bevacizumab or Cetuximab (Fire-3 Trial)

Stahler, A; Stintzing, S; von Einem, JC; Westphalen, CB; Kramer, N; Michl, M; Modest, DP; von Weikersthal, LF; Decker, T; Kiani, A; Heintges, T; Kahl, C; Kullmann, F; Scheithauer, W; Mohler, M; Vehling-Kaiser, U; Kirchner, T; Jung, A; Heinemann, V

ONCOLOGY RESEARCH AND TREATMENT, 2020; 43 (): 48

科室
- - 订阅+
  - 更多科室
工具
服务